← board
QUCY
distress 8/10 · high distress / dilution risk$1.13-1%today-68% from 52w high
Revenue
pre-revenue
Liquidity
$5M
Runway
0.4 yrs
Shares 1y
+17%
Price & events
-4.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.9%
1D
-5.0%
1W
-24.2%
1M
+121.6%
3M
-4.2%
6M
-45.7%
1Y
+218.3%
2Y
—
5Y
-95.7%
All
Overview
- Market Cap
- $16.57M
- Volume
- 111.19K
- 52 Week Range
- $0.32 – $3.56
- Total Shares
- 14.66M
- Float Shares
- 13.48M
- Short %
- 15.26%
- % Held by Insiders
- 6.90%
- % Held by Institutions
- 1.60%
- RVOL
- 0.03x
- Beta
- 2.29
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- 2026-06-11partnershipquantum antenna technology · Exclusive worldwide license for defense and national security drone applicationsSEC 8-K
- 2026-06-01partnershipAmendment No. 1 to Intellectual Property License Agreement with BP United, modifying payment and manufacturing termsSEC 8-K
- 2026-05-26partnershipIP License Agreement and commercial supply arrangement with BP United Inc.SEC 8-K
- 2025-10-03partnershipEntered into equity distribution agreement with Maxim Group LLC for ATM up to $10M.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.